Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of BL-M05D1 in Subjects With Solid Tumors

NCT07021066 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

160

Enrollment

INDUSTRY

Sponsor class

Conditions

Gastric Adenocarcinoma
Advanced Pancreatic Ductal Adenocarcinoma
Esophageal Adenocarcinoma
Biliary Tract Cancer
Other Solid Tumors

Interventions

DRUG: BL-M05D1

Sponsor

SystImmune Inc.